Abeona TherapeuticsABEO
About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
Employees: 84
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,265% more call options, than puts
Call options by funds: $3.88M | Put options by funds: $284K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
25% more capital invested
Capital invested by funds: $145M [Q2] → $182M (+$36.7M) [Q3]
15% more funds holding
Funds holding: 48 [Q2] → 55 (+7) [Q3]
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
17.13% less ownership
Funds ownership: 83.52% [Q2] → 66.38% (-17.13%) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 118 / 313 met price target | 164%upside $15 | Buy Reiterated | 25 Nov 2024 |
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target | 217%upside $18 | Overweight Reiterated | 29 Oct 2024 |